San Diego's Conatus Pharmaceuticals said its in-development liver disease drug came through in a Phase II trial, results the company believes create a path to late-stage development.
BCG (Bacille Calmette-Gu é rin) is the only WHO-approved tuberculosis vaccine and is given to infants, but has proven ineffective in adults. Enter GlaxoSmithKline, which, along with Aeras and Kenya Medical Research Institute, will roll their candidate in Phase IIb trials in Kenya.
Results from the Phase I trial of yet another experimental Ebola vaccine are in, but unlike other vaccines in the field, this one is based on the virus strain that caused the 2014 epidemic, and not an older one. The vaccine, developed by Beijing Institute of Biotechnology and Tianjin CanSino Biotechnology, is called a recombinant adenovirus type-5 vaccine.
MEI Pharma's lead candidate failed to meet its primary goal in a Phase II study on myelodysplastic syndrome, a rare bone marrow disorder that often develops after cancer treatment, sending the biotech trawling for a positive spin on the data.
GlaxoSmithKline is testing its Ebola jab in Africa to see if it provokes an immune response strong enough to successfully beat an Ebola infection. But if it turns out to be too weak, never fear--the Big Pharma has a plan. It's teaming up with Maryland-based Emergent BioSolutions to test the latter's Ebola shot as a booster for its own vaccine.
Actelion has presented detailed data on the drug it hopes will cement its position in the pulmonary arterial hypertension market, Uptravi. The shock-free data drove a small uptick in Actelion's stock, but fell short of being the blockbuster-guaranteeing release some were hoping to see.
About two months ago, Nektar was talking up a big expansion, making way for the new staffers that would be needed to start commercializing the breast cancer drug NKTR-102. Today, the biotech may be rethinking that plan, as the drug failed in a pivotal late-stage study.
Diabetes vaccine developer Diamyd Medical is running a Phase II test to see if its candidate, Diamyd, can prevent or delay the onset of Type 1 diabetes in children at very high risk of presenting with the disease.
The number of Ebola cases in West Africa has been declining, which has made it more difficult to enroll patients for clinical trials of leading vaccine candidates. And the way GlobalData analyst Daian Cheng sees it, that means it's time for vaccine manufacturers to "weigh the risks and benefits of developing further interventions for a disease that goes through unpredictable cycles of intense outbreaks followed by its virtual disappearance."
San Diego-based Acadia Pharmaceuticals put out word on Wednesday evening that it is delaying its expected NDA for pimavanserin from Q1 back to some time in the second half of this year. And the company says its CEO is out the door.